Abstract Context: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) appeared for the first time in December 2019 in …

Introduction An outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
was reported in Wuhan, China, in mid-December 2019, and declared a pandemic by the …

Introduction An outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
was reported in Wuhan, China in mid-December 2019, and declared a pandemic by the …

Background & Aims: Favipiravir is an antiviral drug that is widely used in patients with Covid-
19. The aim of this study was to review the systematic review and meta-analysis studies of …

To the Editor: The COVID-19 pandemic continues to be a global source of concern. Several
therapies have been investigated for COVID-19 including oral antivirals, 1, 2 repurposed …

The novel coronavirus outbreak began in late December 2019 and rapidly spread
worldwide, critically impacting public health systems. A number of already approved and …

Multiple options are being tried for the management of 2019-nCoV infection since its
pandemic started. Favipiravir (FPV) is one of drugs, which is also being tried for the …

Background The role of favipiravir (FVP) as a COVID-19 treatment is recognized but not fully
elucidated. We aimed to evaluate whether FVP has definite clinical efficacy and safety in the …

This meta-analysis was conducted with the aim to assess the safety and efficacy of
favipiravir in treating patients with coronavirus disease 2019 (COVID-19). It was carried out …

To the Editor: COVID-19, an infectious respiratory disease caused by the severe acute
respiratory syndrome coronavirus-2 virus, has exhibited swift transmission rates and …